Nitric oxide mediates a wide array of cellular functions in many tissues. It is generated by three known isoforms of nitric oxide synthases (NOS). Recently, the endothelial isoform, NOSIII, was shown to be abundantly expressed in the rat thyroid gland and its expression increased in goitrous glands.
Introduction
Nitric oxide (NO) is a free radical gas with a very short half-life that is produced in many tissues via the so-called 1-arginine-NO pathway (see 1, 2 for review). NO is synthesized by oxidation of the amino acid 1-arginine by NO synthases (NOS), a family with three known isoforms (3) . The brain (NOSI) and the endothelial (NOSIII) isoforms are constitutive Ca +-calmodulin-dependent enzymes, whereas the third isoform, NOSII, also referred to as macrophage NOS, is an inducible Ca """-independent enzyme regulated at the transcriptional level by mediators such as bacterial endotoxins, interleukins, and interferon- (1) . Besides its classical function as a regulator of vascular blood flow (4) , NO is involved in a wide array of immunological, digestive, neuronal, cardiovascular and secretory processes (2, 5) . More recent studies have also suggested a role for NO in the release of insulin, and hypothalamic, pituitary and steroid hormones (2) .
Using an experimental model of goiter formation and involution in the rat, we recently demonstrated that all three NOS isoforms are expressed in whole thyroid glands and that they are functionally active (6) . Among the isoforms, NOSIII is expressed at the highest level and probably accounts for the major part of the enzyme activity. Because treatment with an NOS inhibitor reduced thyroid vascular expansion during goiter formation, we proposed that NO might modulate the vascular reorganization that occurs in conjunction with thyroid growth (7) .
Based upon studies using stimulators of the phosphoinositol/Ca2+ pathway and blockade of NO synthesis, NO has also been postulated as an autocrine or paracrine stimulator of cyclic GMP production (cGMP) (8) . Treatment with nitroprusside, a precursor of NO, resulted in an increase in cGMP in primary human thyrocytes (9, 10) , and NO is produced in large amounts by human thyroid follicles in culture (11) (6) .
Fifteen microliters of the PCR product of each reaction were electrophoresed through a 6% nondenaturing polyacrylamide gel for 3 h at 300 V Gels were dried on blotting paper and exposed to phosphoimager plates. (Fig. 2) . (Fig. 4) . Immunofluorescence with nuclear counterstaining confirmed the predomi¬ nantly apical localization of the enzyme (Fig. 5) .
Discussion
The three known NOS isoforms have been identified in the rat thyroid gland (6) (29) . In each of these tissues, NO seems to be involved in the modulation of secretory processes.
In the pituitary gland, NO exerts inhibitory actions on prolactin secretion, growth hormone-releasing hormone-induced secretion of growth hormone, and gonadotropin-releasing hormone-induced secretion of luteinizing hormone (29) (30) (31) . A potential involvement of NO in thyroid epithelial cell functions is indirectly suggested by its subcellular localization. NOSIII immunoreactivity was particularly marked in the apical area of the cells and/or in the apical membrane itself (Fig. 4) . The membrane localization, also described in bronchiolar cells (27) 
